- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dr Reddys says Sputnik V 2nd dose shortage to delay India's full rollout
New Delhi: India's full rollout of the Sputnik V COVID-19 vaccine will have to be put on hold until the Russian producer provides equal quantities of its two differing doses, Dr. Reddy's Laboratories Ltd said on Monday.
Dr. Reddy's had received about 3 million first doses by June 1 and about 360,000 doses of the second by early this month, the company and the Indian government have said.
"As a matter of responsibility, we would not like to announce a full-fledged commercial launch until we have an equivalent quantity (of the second dose)," Dr. Reddy's said in an e-mail to Reuters.
Dr. Reddy's, which originally planned a full rollout in mid-June, is currently running a pilot programme under which more than 195,000 doses have been administered at hospitals across the country.
"It is our commitment to ensure supply of component 2 in equal quantity and on time to all partner hospitals to whom we have supplied dose 1," the company said, declining to share more details ahead of its financial results.
India has approved a gap of 21 days between the two doses.
The Russian Direct Investment Fund, which markets the vaccine abroad, did not immediately respond to a request for comment.
The Indian government expects 100 million locally produced and imported Sputnik V doses to be available in the country between August and December. India is expected to be one of the biggest manufacturing hubs of the vaccine.
India has administered more than 375 million vaccine doses, the world's most after China, inoculating 32% of its estimated 944 million adults with at least one dose.
It is mainly relying on the AstraZeneca shot and one developed at home by Bharat Biotech and the state-run Indian Council of Medical Research.
Daily vaccinations hit a national record of 9.2 million doses on June 21 but have dropped to around 4 million per day.
Read also: Delhi: COVID vaccine Sputnik V roll out delayed
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751